Floatz logo

Gedatolisib

Male Reproductive System Disorder

Celcuity IncSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Male Reproductive System Disorder cohort.

Asset / SponsorPhaseRating
STI571
Novartis Pharmaceuticals
Phase 2B
Psma-Hbed-Cc Alf-18
Alessandro D'Agnolo
Phase 2B
Ixabepilone
Cedars-Sinai Medical Center
Phase 2CCC
Darolutamide
Celcuity Inc
Phase 1/2CCC
Epi-506
ESSA Pharmaceuticals
Phase 1/2CC

Same molecule, other indications

Gedatolisib is also rated in:

breast cancerActive
CCC
Indicative · Phase 3
54 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative · Phase 2
50 / 100
View asset →
therapy-related myeloid neoplasmDormant
CCC
Indicative · Phase 2
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →